Advances of Alzheimer’s Research: Outlook on Prevention and Earlier Detection




Neuroscience and Neurology CategoryAn estimated 4.5 million older people currently have Alzheimer’s disease, and researchers predict that by 2050 the number could nearly triple to 13.2 million. But several promising recent developments in the study of Alzheimer’s disease may one day lead to new methods of diagnosing, preventing and slowing the disease’s progress. These include a new way to look inside the brains of people with the disease as well as new methods for preventing buildup of a protein, called amyloid, which forms plaques that scientists believe may be involved in causing Alzheimer’s symptoms.

Detecting Alzheimer’s disease at an earlier stage is a major research goal. In one compelling study that may lead to crucial earlier diagnosis and prevention efforts, scientists created a compound that allows them to use positron emission tomography (PET, an imaging tool used to view body function and diagnose disease) to look at early signs of the abnormal clumps of amyloid proteins (called plaques) that form in the brains of people who have Alzheimer’s. Called Pittsburgh Compound B, the substance was developed by researchers at the University of Pittsburgh School of Medicine and Sweden’s Uppsala University. Their work is aimed at being able to intervene sooner in people with Alzheimer’s, possibly as the plaques begin to form was supported in part by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).

“We are moving toward earlier and earlier detection of Alzheimer’s disease,” notes Dr. Neil Buckholtz of NIA’s Neuroscience and Neuropsychology of Aging Program. “Research at Pittsburgh and elsewhere is bringing us closer to the day when we can look in the brain, see if the characteristics of the disease are there, and then develop therapies that hopefully can change the progression of the disease and its clinical course.” Buckholtz heads a new effort in which NIA is bringing together government, academic and industry scientists to accelerate the use of imaging in research and, ultimately, in the diagnosis and treatment of Alzheimer’s disease.

Stopping Alzheimer’s Plaques

Understanding the formation and activity of beta amyloid, the primary component of Alzheimer’s plaques, is a major focus of research. Investigators continue to work intensely to figure out the process by which amyloid precursor protein (APP) is snipped by enzymes to release the beta amyloid fragments that clump together to form the sticky plaques. One of these enzymes is called beta secretase. In a mouse study at Johns Hopkins University School of Medicine, scientists developed a transgenic mouse in which the gene for BACE1, a beta secretase enzyme, is eliminated, or “knocked out.” The scientists found that with BACE1 eliminated, beta amyloid protein fragments were no longer produced in brain cell cultures of the knockout mice. This finding has resulted in a focus on the design of drugs that could inhibit BACE1 activity.

Earlier NIH-supported studies also discovered potential mechanisms to clear amyloid plaques. Researchers at the Salk Institute and their colleagues elsewhere found that gene transfer of an enzyme may help clear out plaques. The human enzyme, neprilysin, was injected into the brains of transgenic mice with human amyloid plaques. After the treatment, the enzyme appeared to help degrade existing plaques and help reduce growth of new plaques.

Teams of scientists in New York and California have suggested that astrocytes, one of the three principal types of brain cells, can break down amyloid and eliminate it from the brain. Astrocytes nourish and protect neurons in the brain and are located close to brain plaques. Researchers have a theory that some astrocytes may be impaired, making them unable to, in Alzheimer’s case, completely clear amyloid from the brain.

“Our studies on the biology of Alzheimer’s disease give us an increasingly clear picture of what happens in the brain and how the communications among cells are compromised,” says Dr. Stephen Snyder of NIA’s Etiology of Alzheimer’s Section. “With this knowledge, scientists are now able to demonstrate ways in which the culprits involved in Alzheimer’s might be interfered with and even eliminated.”

Possible Treatments Under Study

Some research is turning to old drugs for their potential promise in treating Alzheimer’s disease. In one study at Massachusetts General Hospital, scientists funded by NIA and NIH’s National Institute of Mental Health (NIMH) examined a rarely used antibiotic that seemed to dissolve the plaques. The drug, clioquinol, was chosen because it draws zinc and copper from the body. Some scientists believe that when amyloid is present, it attracts zinc and copper, paving the way for destructive brain plaques to form. The team found that treatment with clioquinol reversed the deposition of amyloid in the brains of mice with AD. Despite these encouraging findings, researchers need to proceed very cautiously when investigating this compound for human use, as small amounts of these metals are necessary for many chemical reactions in the body.

Other widely used medications are currently being tested. One population study published two years ago found that people with elevated levels of a compound called homocysteine in their blood had nearly double the risk of developing Alzheimer’s. Blood levels of homocysteine can be reduced by increasing intake of folic acid (or folate) and vitamins B6 and B12. Researchers are now examining whether lowering homocysteine levels in the blood with B vitamins and folate might reduce the risk of Alzheimer’s. Results of this trial are expected in late 2006.

Researchers are also studying simvastatin, a cholesterol-lowering drug, in people who already have Alzheimer’s disease to see if the drug might slow down the rate of Alzheimer’s progression. Earlier studies have associated the use of cholesterol-lowering drugs in this class with a positive impact on brain function and reduced risk of Alzheimer’s. Results of this trial are expected in late 2006.

Where Research Is Headed

In addition to looking for ways to diagnose and treat Alzheimer’s earlier, researchers are examining lifestyle and genetic factors that might affect a person’s chances of developing the disease.

Diet and exercise, for example, are under close study. Another interesting avenue being explored is the influence of formal education on a person’s memory and learning skills. Researchers are trying to determine if the amount of formal education a person has somehow affects the brain so that it facilitates a person’s potential to work around or reduce the effect of the brain abnormalities associated with Alzheimer’s.

To examine how heredity and genes play a role in Alzheimer’s, NIA recently stepped up its Alzheimer’s Disease Genetics Initiative. The initiative teams up NIA, academic researchers at Indiana University and Columbia University, the NIA-supported network of 29 Alzheimer’s Disease Centers around the U.S., and the Alzheimer’s Association. Scientists hope to create a large bank of data and blood cells containing genetic material from 1,000 families in which at least two living siblings have been diagnosed with late-onset Alzheimer’s disease. By studying families with the late-onset form of Alzheimer’s, the most common form of the disease, scientists hope to understand more about how Alzheimer’s develops as well as new methods of prevention and treatment. To find out how to participate in the study, families should contact the National Cell Repository for Alzheimer’s Disease (NCRAD).

“Finding the additional risk factor genes for late-onset AD is critically important to move our understanding forward,” says Dr. Creighton Phelps, director of the program that supports the NIA Alzheimer’s Centers. “Working intensively with a large number of families will, we hope, allow scientists to find these genes sooner rather than later.”

Scientists still need to learn a lot more about what causes Alzheimer’s disease. By studying genetics, education, diet, environment, and other factors to learn what role they might play in the development of this disease, researchers hope they will find ways to diagnose, prevent or even treat this devastating illness. To keep up to date on new developments, visit Alzheimer’s Disease Education & Referral Center. Adopted from the National Institutes of Health.

  • Charles E. Donovan

    NEW ALHZEIMER’s TREATMENT: Scientists are discovering that there are many new implications for stimulating the vagus nerve. It is absolutely amazing.

    The clue to curing many chronics diseases once thought incurable are now being found in stimulating the vagus nerve. The Journal of Psychiatry just reported that vagus nerve stimulation (VNS) is safe and beneficial for some patients with Alzheimer’s Disease. It is the identical procedure that I had for depression, which is also the identical procedure performed in epilepsy patients.

    This incredibly important study showed that VNS is well tolerated and safe in patients with Alzheimer’s disease. Furthermore, the study indicated that VNS may be of benefit, as a cognitive enhancing therapy. Just over 50% of patients showed improvement or no decline in the Alzheimer Disease. Furthermore 70.6% of patients had improvement or no decline from baseline on the Mini-Mental Status Examination(MMSE)

    To learn more visit MyDepressionSpace.com

Shaheen E Lakhan, MD, PhD, MEd, MS

Shaheen E Lakhan, MD, PhD, MEd, MS, is a board-certified neurologist, pain medicine specialist, medical educator, and executive director of the Global Neuroscience Initiative Foundation (GNIF). He is a published scholar in biomarkers, biotechnology, education technology, and neurology. He serves on the editorial board of several scholarly publications and has been honored by the U.S. President and Congress.
See All Posts By The Author

Do not miss out ever again. Subscribe to get our newsletter delivered to your inbox a few times a month.